✦ 24h Briefing Top Stories World U.S.India Business Technology Science Health Sports Entertainment

Loading

Fetching the latest headlines…

NabkaNews aggregates headlines from thousands of publishers worldwide via Google News, and provides AI-generated summaries and briefings for convenience. Every story links to its original source. We do not host or claim ownership of third-party reporting, and AI summaries may contain errors — always verify with the original source.

24h Briefing Top Stories World U.S.India Business Technology Science Health Sports Entertainment

Disclaimer Privacy Policy Terms of Use

© 2026 NabkaNews · World · U.S. · India — updated continuously. NabkaNews is an independent news aggregator and is not affiliated with any publisher shown.

FDA lifts hold on an Intellia CRISPR drug trial · NabkaNews

← Back to headlines

FDA lifts hold on an Intellia CRISPR drug trial

BioPharma Dive·Jan 27

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA has lifted a hold on an Intellia CRISPR drug trial, allowing it to resume. The trial is for a gene therapy, with some reports specifying it is for a heart disease study, although the specific condition and details of the trial are somewhat unclear. The lift of the hold has reportedly led to a rise in Intellia's shares.

Full coverage

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Intellia Therapeutics·Mar 2

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

Fierce Biotech·Mar 2

Intellia gets FDA nod to resume one gene therapy trial after safety pause

Reuters·Jan 27

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials

NeurologyLive·Jan 28

Intellia gets FDA nod to resume gene therapy trial after safety pause

Yahoo Finance·Jan 27

Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold

BioSpace·Mar 3

Intellia's shares rise as FDA hold lifts

FirstWord Pharma·Mar 2

FDA ends trial halt on 1,200-patient heart disease study

Stock Titan·Mar 2

View original report at BioPharma Dive ↗